MAI-001 by Nanjing Minova Pharmaceutical Technology for Depression: Likelihood of Approval

MAI-001 is under clinical development by Nanjing Minova Pharmaceutical Technology and currently in Phase I for Depression.

Labcorp to lay off 239 workers in New Jersey amid biotech slump

Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief: Labcorp plans to lay off

November 22, 2023

Abivax announces Closing of its Initial Public Offering on the Nasdaq Global Market – Biotech Investments

EQS-News: ABIVAX / Key word(s): IPO Abivax announces Closing of its Initial Public Offering on the Nasdaq Global Market 24.10.2023 / 22:05 CET/CEST The issuer

October 25, 2023

Pentixapharm Welcomes CMS Decision to Enhance Reimbursement for Diagnostic Radiopharmaceuticals – Biotech Investments

EQS-News: Pentixapharm Holding AG / Key word(s): Statement Pentixapharm Welcomes CMS Decision to Enhance Reimbursement for Diagnostic Radiopharmaceuticals 04.11.2024 / 17:26 CET/CEST The issuer is

November 5, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.